This drug is commonly prescribed for type 2 diabetes, but the NHS says to seek immediate medical help for three side effects ...

The use of SGLT2 inhibitors, especially dapagliflozin, can lower adiposopathy parameters in patients with CKD, regardless of ...

Review the side-effects of Dapagliflozin as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

Dapagliflozin is mainly prescribed for type 2 diabetes, but it is also used to treat heart failure and chronic kidney disease ...

The sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin (Farxiga) met its primary endpoint in the DELIVER phase III trial by significantly lowering the risk of cardiovascular death or ...

Competing trials are under way that may show that the benefits of SGLT2 inhibitors in heart failure are a class effect. Sodium glucose cotransporter 2 (SGLT2) inhibitors, first approved to treat type ...

Dapagliflozin, an oral SGLT2 inhibitor, decreased the risk of progression of focal segmental glomerulosclerosis compared with placebo, a subgroup analysis of the DAPA-CKD trial showed. The ...

PHILADELPHIA, PA—Dapagliflozin (Farxiga; AstraZeneca), originally developed for the treatment of type 2 diabetes, has a broad, positive impact across various subsets of patients with chronic heart ...

Dapagliflozin is currently indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D). In the United States, it is also approved to reduce the risk ...

The NHS has warned people taking dapagliflozin to seek urgent medical help if they notice three specific symptoms, ...

In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms.